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Summary 
A  T  helper  type  1  (Thl)-mediated  colitis with  similarities  to inflammatory bowel disease  in 
humans developed in severe combined immunodeficiency mice reconstituted with CD45R_B  high 
CD4 + splenic T  ceils and could be prevented by cotransfer ofCD45RB l~  CD4 + T  cells.  Inhi- 
bition of this Thl  response by the CD45ILB  l~  T  cell population could be reversed in vivo by 
an anti-transforming growth factor (TGF)  13 antibody. Interleukin (IL) 4 was not required for ei- 
ther the  differentiation  or function of protective  cells  as CD45RB  l~  CD4 + cells from IL-4- 
deficient mice were fully effective. These results identify a subpopulation of peripheral  CD4 + 
cells and TGF-13 as critical components of the natural immune regulatory mechanism,  which 
prevents the development of pathogenic Thl responses in the gut, and suggests that this immu- 
noregulatory population is distinct from Th2 cells. 
M  ucosal immune responses are highly regulated to al- 
.low activation of effector mechanisms that eliminate 
pathogenic  microorganisms  while  specifically  preventing 
cell-mediated  inflammatory responses  against  dietary  anti- 
gens and  enteric  flora.  It has been suggested that a break- 
down  in  this  mucosal  immune  regulation  is  important  in 
the development of idiopathic inflammatory bowel disease 
(IBD) in humans (1).  Dissection of the regulatory pathways 
that act normally to prevent the development of pathogenic 
immune responses in the intestine  may therefore be key to 
the understanding of the pathogenesis of human IBD. 
We and others have described a model of colitis in mice 
that has proven useful for dissecting the mechanisms of this 
form of immune regulation. Colitis was induced in immuno- 
deficient C.B-17 sdd mice by transfer of  the CD45RB  ~gh sub- 
set of CD4 +  T  cells from normal C.B-17  (2)  or congenic 
BALB/c (3,  4) donors. Progressive colon inflammation was 
caused by a dysregulated Thl response as CD4 + T  cells pu- 
rified  from the  lamina  propria  of diseased  mice produced 
very high levels of IFN-y, and TNF  and disease  was pre- 
vented by systemic treatment  with antibodies  to IFN-'y or 
TNF or with recombinant IL-10 (4).  Significantly, transfer 
of the  reciprocal CD45RB l~  population  did not result in 
disease,  and  this  population,  when  transferred  together 
with CD45RBhighCD4 + T  cells,  completely inhibited  dis- 
ease  development  (3-5).  These  data  identify a subpopu- 
lation  of CD4 +  T  cells,  present  in  normal  mice,  that  are 
critical  for the  regulation  of pathogenic  Thl  responses  in 
the gut. 
It seems likely that the inhibition of colitis transferred by 
CD45RB  l~  cells is mediated via the production of immu- 
nosuppressive  cytokines.  Th2  cells  are  known  to  inhibit 
Thl  effector cell development and function, principally by 
the  production  of IL-4  and  IL-10  (6-8).  More  recently, 
TGF-13 has been shown to be  a  mediator  of the  induced 
suppression  associated with  oral tolerance  to foreign anti- 
gens  (9,  10).  Such TGF-13-producing regulatory  cells  are 
often found together with Th2-1ike cells;  however, it is not 
known whether these cells constitute part of the Th2 subset 
or represent  a  distinct  subset  of cells.  Here,  we  use neu- 
tralizing anti-TGF-13 mAbs and IL-4-deficient mice to ex- 
amine  the  role  of these  cytokines  in  the  suppression  of 
Thl-mediated  colitis by CD45RBl~  + T  ceils  and to 
examine the relationship of regulatory cells to Th2 cells. 
Materials and Methods 
Mice.  Specific pathogen-flee BALB/c and C.B-17 scid mice 
were  obtained from Simonsen Laboratories  (Gilroy,  CA);  129/ 
SvEv mice were  obtained from Taconic Farms,  Inc.  (German- 
town, NY). Mice were maintained in the Animal Care Facility of 
the DNAX Research Institute.  129SvEv RAG-2-deficient mice 
and 129/J IL4T and 129 SvEv IL-4T (IL-4-deficient) mice were 
bred and maintained in the Animal Care Facility  of the DNAX 
Research Institute.  C.B-17 scid mice and P,-AG-2-deficient mice 
were housed in microisolator cages with sterile  filtered  air.  Fe- 
male mice were used at 8-12 wk of age. 
Antibodies.  The following mAbs were used for cell purifica- 
tion: AMS-32.1, anti-l-A  d (PharMingen, San Diego, CA); 2-43, 
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Rockville, MD); M1/70, anti-mouse Mac-1 (TIB128; American 
Type  Culture  Collection);  RA3-6B2,  anti-mouse  B220  (11); 
FITC-conjugated 16A, anti-mouse CD45RB (PharMingen);  PE- 
conjugated anti-mouse CD4 (Becton Dickinson & Co., Moun- 
tain  View,  CA);  and  PE-conjugated  isotype  control  mAb 
(PharMingen).  The following mAbs were used in vivo: 1Dll. 16 
(mouse  IgG1),  anti-TGFq31,  2,  and  3  (12),  and  1410KG7 
(mouse  IgG1) isotype control rnAb (12). For in vivo use, mAbs 
were purified by column chromatography from tissue culture su- 
pernatants.  The resulting  antibodies  were >98% pure  and con- 
tained <3 EU endotoxin per milligram  of protein. 
Cell Purification and Flow Cytofluorography.  CD4 + T cell subsets 
were purified from the spleens  of mice as previously described 
(3). Briefly, cells were depleted  of B220  +, MAC-1 +,  I-A  a+, and 
CD8 +  cells by  negative  selection  using  sheep  anti-rat-coated 
Dynabeads (Robbins Scientific  Corp., Sunnyvale,  CA). The re- 
maining  cells were labeled with  FITC-conjugated anti-CD45RB 
(25  ~g/ml)  and PE-conjugated anti-CD4  and fractionated  into 
CD4+CD45RB  high and CD4+CD45RB  l~  fractions by two-color 
sorting on a FACSTAR  |  PLUS (Becton Dickinson & Co.). All 
populations were >98% pure on reanalysis. 
Reconstitution of C.B-17  scid Mice with  T  Ceil Subpopulations. 
C.B-17 scid mice were injected intraperitoneally  with  100 btl of 
PBS  containing sorted CD4 + T  cell  subpopulations or unsepa- 
rated CD4 + T cells. Anticytokine or control mAbs were injected 
intraperitoneally  in PBS. 
Microscopic Examination of Colons.  Colons were removed from 
mice 8-18 wk after T  cell reconstitution and fixed in PBS con- 
taining  10%  formaldehyde.  6-p~m paraffin-embedded  sections 
were  cut and stained  with  hematoxilin  and  eosin.  Microscopic 
sections  were  graded semiquantitatively  as  0  (no  change)  to  5 
(most severe) in a blinded fashion by the same pathologist (M.W. 
Leach). 
Nucleic Acid  Preparation and  Semiquantitative PCR of Cytokine 
mRNA.  Quantitation ofcytokine mRNA in the colon was per- 
formed as previously described  (3). Briefly,  RNA was prepared 
from 40-200-rag pieces  of distal colon by a modification of the 
guanidium  isothiocyanate method.  2-3  p~g of RNA  from test 
samples  was  reverse  transcribed  using  Superscriptase  II RNAse 
H-reverse transcriptase (GIBCO BRL, Gaithersburg, MD). IFN-y, 
TNF-Ix,  and  hypoxanthine phosphoribosyl transferase  (HPRT) 
cDNAs were amplified by PCR and detected by dot blot hybrid- 
ization  and  phosphoimaging.  Relative  quantitation  of samples 
was  performed using quantitation  of the  housekeeping enzyme 
HPRT as an internal  standard.  HPRT levels in the samples were 
measured first,  and samples with  equivalent amounts of HPRT 
were then analyzed  for cytokine cDNA. For each cytokine, the 
standard Th cDNA was run and specific cytokine levels were de- 
termined (IFN-3' 156 -  1.2 pg, TNF-ci 10 -  0.019 rig). Units of 
specific cytokine were determined for each sample by comparison 
with a standard curve constructed with cDNA from pooled RNA 
of  an activated Thl and Th2 clone.  1 U ofcytokine was defined as 
the  amount  in  l  ng Th  standard  cDNA,  and  values  were  ex- 
pressed as units of cytokine/105 U HPRT. 
Results 
Suppression  of Colitis  by CD45RB  t~  CD4 + T  Cells Is De- 
pendent on TGF-fl.  In previous studies, mice restored with 
CD45RB high and CD45RBl~  + T  cells  remained pro- 
tected from colitis when treated with anti-IL-4, anti-IL-10, 
or both mAbs (5),  suggesting that suppression of colitis was 
mediated  by other  immunosuppressive  cytokines.  To  test 
the  role  of TGF-[3,  mice reconstituted  with  CD45R_Bhig h 
and CD45RBI~  + cells were treated with a mouse rnAb 
that neutralized TGF-[31, 2, and 3 (12). In the initial exper- 
iments  (Table  1, protocol 1),  mice were treated with 2  mg 
anti-TGF-[3 at the time ofreconstitution followed by 1 mg 
weekly for 6  wk and then killed for histological examina- 
tion  at  7  wk  after  transfer.  Neutralization  of TGF-[3 par- 
tially,  but significantly,  diminished the ability of CD45RB l~ 
T  cells  to protect from colitis.  The average colitis score in 
these mice was 2, and 6 of 11 mice developed severe colitis 
compared with an average colitis score of 0.3 and zero inci- 
dence of severe colitis in isotype control-treated mice (Ta- 
ble 1, protocol 1). Anti-TGF-[3-treated mice that developed 
severe  colitis  also  developed  a  wasting  disease,  indistin- 
guishable  from  mice  restored  with  CD45R_BhighCD4 +  T 
cells  alone  (Table  1).  Anti-TGF-[3 treatment  of unrecon- 
stituted scid mice  (Table  1)  or scid mice reconstituted  only 
with CD45RBI~  + T  cells  alone  (data not shown)  did 
not induce colitis or wasting, demonstrating that the antibody 
did not cause disease  in the absence of the CD45R_B  high pop- 
ulation. 
To  address  the possibility that insufficient  antibody was 
being administered  to  inhibit  TGF-[3  activity completely, 
the weekly dose of anti-TGF-[3 was doubled to 2  mg/wk 
in  subsequent  experiments  (Table  1,  protocol  2).  At  this 
dose,  100% (7/7)  of mice given a mixture  of CD45RB high 
and CD45RB1~  + T  cells  developed severe colitis and 
wasting  disease,  a  frequency  indistinguishable  from  mice 
given CD45RBhighCD4 +  T  cells  alone.  The  colitis  in  the 
two  groups of mice was histologically identical  (Fig.  1, A 
and  B),  being  characterized  by a  prominent  lymphocytic 
infiltrate,  extensive  epithelial  cell  hyperplasia,  and  goblet 
cell depletion. Mice given the mixture of CD45RB high and 
CD45RB l~  cells  and  treated  with  isotype  control  mAb 
were completely protected from these pathological changes 
(Fig.  1 C). 
Colitis Induced in Recipients of CD45RB  h~eh and CD45RB  l'w 
CD4 + T  Cells  Treated with Anti-TGF-fl  Is Identical to Colitis 
Induced by CD45RB  h~h Cells Alone.  Colitis  induced by the 
CD45Pd3highCD4 + population has been shown to be a Thl 
response mediated by IFN-y and  TNF  (4).  To  determine 
whether the disease that developed in anti-TGF-~-treated 
mice  restored  with  both  CD45RBhig  h  and  CD45RB l~ 
cells had a similar pathogenesis,  colons were isolated from 
these  mice 7  wk after T  cell  reconstitution  and  tested  by 
reverse  transcriptase-PCP,,  analysis  for  the  expression  of 
IFN-y  and  TNF-ci  mRNA  (Fig.  2).  Mice  restored  with 
CD45R-B  high cells  and mice restored with CD45RB  high and 
CD45RB  l~  cells and treated with anti-TGF-[3 had 7-8- and 
6-10-fold higher levels, respectively, of TNF-ci and IFN-y 
mRNA  than  mice  protected  from colitis  by  cotransfer  of 
both  T  cell  subsets.  The  extensive  similarities  in  kinetics, 
histology,  and  cytokine  mRNA  expression  between  the 
diseases  caused by CD45R.B high T  cells  without the regula- 
tory population,  and  CD45RB h~gh T  cells  plus  the  regula- 
tory population and anti-TGF-[3 demonstrate that TGF-[3 is 
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Protocol 1  Protocol 2 
Number of  Number of 
Phenotype of CD4 + T  mice with  Weight  mice with  Weight 
cell inoculum  Colitis score*  severe colitis*  6w/0w %g  Colitis score*  severe colitis*  6w/0w %~ 
4  >  105 CD45RBhig  h  113.3 +  0.3  8/10  e89.7  -+ 2  I/2.9 +  0.1  9/10  1189.9 +  2 
4  X  10 5 CD45RB h~gh 
+  2  ￿  105 CD45RB  l~ 
+  anti-TGF-[3 mAb  112.0 __+  0.4  6/11  11,￿82  +  4  113.1 __  0.1  7/7  1187.9 +  1 
4  ￿  l0  s CD45R-B  high 
+  2  ￿  105 CD45RB l~ 
+  isotype control mAb  0.3  _  0.2  0/11  110.8  -  3  **0 -  0  0/7  104.2  _  4 
Unreconstimted SCID 
+  anti-TGF-13 mAb  0  4- 0  0/5  108.3  -+ 3  ND  ND  ND 
C.B-17 scid mice were injected intraperitoneaUy with sorted CD4 + T cell subsets; some mice were treated with anti-TGF-13  or isotype control mAb 
intraperitoneally  as indicated.  Protocol 1 contains pooled data from two independent experiments in which antibody treated mice were given 2 mg 
mAb at the time of T cell reconstitution and 1 nag weekly up to 6 wk. Protocol 2 contains  data from one experiment in which antibody-treated 
mice were given 2 mg mAb weekly up to 6 wk. 
"7 wk after reconstitution, mice were killed and colon pathology was graded. Data represent the mean colitis score plus SE. 
*Severe colitis means grade 3 and above. 
~Weight at 6 wk as a percentage of starting weight. Data represent the mean with SE for the group. 
IIStatistically significantly different (P <0.05, Wilcoxin rank sum test) to mice restored with 4 X 105 CD45RB~g  h +  2 ￿  105 CD45RB  l~  +  isotype 
control mAb. 
￿82  loss of  mice in group with severe colitis. 
*'Mice in this group were not treated with isotype control mAb. 
a  key mediator of the regulatory activity of CD45RB l~  T 
cells, rather than a  direct inducer of an unrelated colon in- 
flammation. 
Differentiation  and  Effector  Function  of  the  Regulatory 
CD45RB  l~  Population Is IL-4 Independent.  Inhibition  of 
colitis by  CD45RB j~  CD4 +  T  cells was not blocked by 
administration of anti-IL-4 mAbs (5),  suggesting that IL-4 
production  was  not  necessary for  the  TGF-13--dependent 
regulatory  mechanism.  However,  these  experiments  did 
not establish whether IL-4 was necessary for the develop- 
Figure  1.  Treatment  with anti-TGF-13 
mAb  abrogates  protection  from  colitis 
transferred by CD45RBI~  + T  cells. 
Severe colitis in C.B-17 sdd mice restored 
with  (A)  4  ￿  105  CD45RBhI~-CD4+ 
cells or (B) 4 ￿  105 CD45RB ~gh plus 2 ￿ 
105 CD45RBl~  + cells, treated weekly 
with 2 mg. anti-TGF-13 mAb as described 
in Table  1.  (C) Protection from colitis in 
mice restored with 4  X  10  s CD45RB high 
plus 2  ￿  105 CD45RBI~  + cells and 
treated weekly with isotype control mAb. 
Colon sections were stained with hema- 
toxylin and eosin and photographed.  ￿  90. 
2671  Powrie et al.  Brief Definitive Report 4 x 105 CD4  + CD45RBhig h + 
2 x 105 CD4  + CD45RB  I~ 
4 x 105 CD4  + CD45RB  hi gh+ 
2 x 105 CD4  + ClM5RB  I~ 
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Figure 2.  Elevations in Thl  cytokine mRNA in the colon of mice 
with severe colitis. 7 wk after T cell reconstitution  scid mice were killed, 
and the levels of cytokine mRNA in the colons were determined by 
semiquantitative  reverse transcriptase-PCR. Values are expressed as units 
of cytokine  per 105 U HPR.T. Data represent the mean plus SEM of three 
animals per group. A repeat experiment gave a similar  result. 
ment of the regulatory population of cells themselves. The 
relationship, if any, between Th2  cells  and TGF-~-pro- 
ducing regulatory  ceils  is  not yet  clear,  although  several 
lines of evidence suggest a  common origin. T  cell clones 
from orally tolerized mice include many that secrete TGF-13 
and the Th2 cytokines IL-4 and IL-10 (10), and some hu- 
man  Th2-1ike  clones  change  to  TGFq3-producing ceils 
when stimulated with altered peptide ligands (13).  IL-4 is 
the only known inducer of Th2 differentiation in mice (14, 
15), and a requirement for IL-4 in the development of reg- 
ulatory CD45RB  l~  ceils would provide additional support 
for a relationship between the two populations. To address 
this,  CD45R.B  l~  cells from  IL-4-deficient and wild-type 
(WT) mice were compared for their ability to inhibit colitis 
induced by WT  CD45RB  high cells.  As IL-4-deficient mice 
were  available  on  the  129  but  not  the  BALB/c  back- 
ground,  RAG-2-deficient mice  on  the  129  background 
were used as immunodeficient  recipients. The great major- 
ity  of 1KAG-2-deficient mice  restored  with  CD45R_B  hlgh 
CD4 + T  cells from syngeneic donors developed colitis very 
similar  to  that  observed  in  C.B-17  scid  mice  (Table  2). 
CD45RBl~  + T  cells were present in both IL-4-defi- 
cient and WT mice (data not shown), and the populations 
from  both  mice  were  equally  able  to  inhibit colitis  and 
wasting disease.  The average grade  of colitis in the  group 
reconstituted with IL-4-deficient cells was 0.8, and only 1 
of 21  mice developed severe colitis (Table 2).  In one ex- 
periment, neutralizing doses of the  anti-IL-4 mAb 11Bll 
were  administered  weekly  to  mice  reconstituted  with 
CD45I~B  high cells from WT  donors and CD45KB  l~  cells 
from IL-4-deficient mice to block any possible IL-4 pro- 
duction from  sources  other  than  the  donor  CD45R_B  i~ 
population.  These  mice  were  still  significantly protected 
from severe colitis (data not shown), demonstrating unam- 
biguously that  the  regulatory population of CD45RB  i~ 
ceils is present and mediates its immunoregulatory function 
in IL-4-deficient mice. 
Table 2.  Protection  from Colitis  Transferred by CD45RB  I~ 
CD4 + T  Cells is IL-4 Independent 
Number of 
Phenotype of CD4 + T  Colitis  mice with  Weight 
cell inoculum  score*  severe colitisa  9W/0W%~ 
4 ￿  10  s CD451KB  higF'  f13.l +  0.35  13/17  U84.3 _+ 2.5 
4 ￿  10  s CD45Pd3  high 
+  2 ￿  10  s CD45RB  ~~  0.8  +_ 0.3  4/19  104.7 +  5.3 
4 ￿  10  s CD45RB  high 
+  2 X 10  s CD45RB  l~ 
IL-4 deficient  0.3  _+ 0.2  1/21  107.7 +  2.7 
2 ￿  10  s CD45RB  l~ 
IL-4 deficient  0 +  0  0/5  ND 
CD4 + T cell subsets were isolated from the spleen of 129SvEv or IL-4- 
deficient 129/.1 or  129SvEv mice and injected intraperitoneally into 
129SvEv RAG-2-deficient mice. Data represent three independent ex- 
periments; in two of these, 129/J IL-4--deficient  mice were used as a 
source ofCD45RB  t~  cells, and m a third experiment, 129SvEv IL-4- 
deficient mice were used, Results using these two strains were sinfilar 
therefore data were pooled. 
*20 wk after reconstitution, nfice  were killed and colon pathology was 
graded. Data represent the mean colitis score plus SE. 
:~Severe colitis means grade 3 and above. 
~Weight at 9 wk as a percentage of starting weight. Data represent the 
mean with SE for the group. 
IlStatistically  significantly  different (P <0.05, Wilcoxin rank sum test) to 
mice restored with 4 ￿  105 CD45RB hlgh +  2 ￿  10  s CD451KB  I''w cells 
from WT mice. 
Discussion 
The experiments presented here identify a subpopulation 
ofCD4 + T  cells that is present in normal mice and is essen- 
tial for  the  prevention of Thl-mediated inflammation in 
the intestine. Inhibition of colitis by CD45RB  l~  cells was 
completely ablated by an anti-TGF-[3 mAb, providing di- 
rect evidence that TGF-[3 is an important mediator of the 
natural immune regulatory mechanism involved in control 
of intestinal immune  responses.  Immunoregulatory sub- 
populations of CD4 § T  cells that have the ability to inhibit 
the  development  of spontaneous  organ-specific  autoim- 
mune diseases,  including thyroiditis, gastritis, oophritis, and 
diabetes,  have  been  identified in  normal  mice  and  rats; 
however,  their mechanism of action has  not been deter- 
mined (16-18).  It  is  possible that  TGF-I3 plays  a  similar 
role in this active mechanism of peripheral tolerance, as has 
been  established here  for  the  regulation of mucosal  im- 
mune responses. 
The  suppression of Thl  responses has  been shown,  in 
some instances, to  be  a property  of Th2  cells, in part by 
production of IL-4  (5,  19,  20).  In this  model  of colitis, 
however, the protection could not be blocked by an anti- 
IL-4 mAb  (5),  and CD45RB  l~  cells isolated from IL-4- 
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the  same population  isolated from WT  mice.  Taken  to- 
gether, these data indicate that the TGF-[3-dependent reg- 
ulatory population both develops and functions normally in 
the absence of IL-4. Recently, similar forms of colitis have 
been  shown  to  develop  in  TCR.-Ix chain-deficient  mice 
(21),  IL-2-deficient mice  (22),  and  IL-10-deficient mice 
(23), .among others, providing support for the idea that in- 
testinal immune responses are regulated normally by a sub- 
population of regulatory T  cells  (24).  Whether these other 
models  are  deficient in  the  TGF-[3-dependent regulation 
described here remains to be established. 
There is now a large body of data correlating the induc- 
tion of TGF-[3 with a subsequent state of antigen-specific 
systemic hyporesponsiveness induced by oral administration 
of antigen (25).  CD4 + T  cell clones (10)  and CD8 + popu- 
lations (9)  derived from mice fed myelin basic protein were 
able to inhibit the induction of active experimental allergic 
encephalomyelitis,  a  Thl-mediated  autoimmune  disease, 
by a mechanism that involved TGF-[3. Many of the regula- 
tory  CD4 +  T  cell  clones  also  secreted  IL-4  and  IL-10; 
however, the roles of these cytokines in the regulatory ac- 
tivity of the  clones were not tested.  The present findings 
identify TGF-[3 as a key inhibitor  of pathogenic  Thl  re- 
sponses in a very different disease  model and show the im- 
portance of this mode of regulation in normal mucosal un- 
responsiveness in vivo. 
TGF-[31-deficient mice developed a severe multiple or- 
gan inflammatory disease that was lethal by 3-5 wk of age, 
with the most severe lesions being present in the heart and 
lungs  (26,  27).  The  cellular infiltration  in  affected organs 
was associated with increases in the inflammatory cytokines 
IFN-~/and TNF-ot (26),  suggesting that TGF-[31 is impor- 
tant  for the  prevention  of dysregulated  inflammatory re- 
sponses in many organs. Interestingly, inflammation in the 
intestine  of the TGF-[31-deficient mice was usually mild, 
although gastric inflammation was severe on some genetic 
backgrounds. These observations appear to be at odds with 
the findings from the scid transfer experiments, in which an 
absence  of CD45RB  l~  TGF-[3-dependent regulatory cells 
led  to  the  development of severe inflammation restricted 
primarily to the colon. Mild inflammation was seen in the 
lung  and  stomach  of  some  scid mice  restored  with 
CD45RBhighCD4 + T  cells (3). This difference may be re- 
lated to (a) a strain dependency in the susceptibility of mice 
to  develop  colitis,  or  (b)  the  presence  of TGF-[32  and 
TGF-[33 in  TGF-[31-deficient mice, isoforms that would 
be  inhibited  in  reconstituted  scid mice  treated  with  the 
mAb that neutralizes all three isoforms ofTGF-[3. TGF-[31, 
2, and 3 have all been shown to be present in murine small 
and large intestine  (28),  and it may be that  TGF-[32  and 
TGF-[33 play a protective role in the intestine of TGF-[31- 
deficient mice. 
In  summary,  the  finding  that  suppression  of colitis  by 
CD45RB l~  cells was dependent  on TGF-[3 but indepen- 
dent  of IL-4  has  provided  valuable  information  on  the 
mechanism  of action  of these  natural  regulatory  cells.  A 
thorough understanding of the development, effector func- 
tion,  and  antigen  specificity of these  cells  will  provide  a 
backbone of information with which to devise immune in- 
terventions  favoring the  development  of TGF-[3-depen- 
dent regulatory cells rather than pathogenic Thl responses. 
Such  immune  therapy  may be  useful  for  treatment  of a 
number of autoimmune diseases,  including IBD. 
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